Tiziana Life Sciences to Present at the BIO CEO & Investor Digital Conference
February 16 2021 - 10:02AM
Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or
the "Company"), a biotechnology company focused on innovative
therapeutics for oncology, inflammation, and infectious
diseases, today announced that it is presenting at the BIO CEO
& Investor Digital Conference, 16-18th February 2021.
Dr. Kunwar Shailubhai, CEO and CSO of Tiziana
Life Sciences, commented, “I look forward to sharing our exciting
story with conference attendees. With the release of our topline
data from our COVID-19 trial, multiple Phase 2 trial launches
expected in 2021, and the potential application of Foralumab in a
wide range of autoimmune and inflammatory diseases in the
longer-term, we are well positioned to achieve a series of
important milestones in the months and quarters ahead.”
Tiziana Life Sciences presentation will be
accessible on demand during the virtual event for all registered
attendees.
Please visit
http://www.tizianalifesciences.com/about-us/ or www.TLSAinfo.com
for more information and to view the latest investor
presentation.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology
company that focuses on the discovery and development of novel
molecules to treat human disease in oncology and immunology. In
addition to Milciclib, the Company is also developing Foralumab for
liver diseases. Foralumab is the only fully human anti-CD3
monoclonal antibody in clinical development in the world. This
Phase 2 compound has potential application in a wide range of
autoimmune and inflammatory diseases, such as nonalcoholic
steatohepatitis (NASH), ulcerative colitis, multiple sclerosis,
type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid
arthritis, where modulation of a T-cell response is desirable. The
company is accelerating development of anti-Interleukin 6 receptor
(IL6R) mAb, a fully human monoclonal antibody for treatment of
IL6-induced inflammation, especially for treatment of COVID-19
patients.
For further enquiries:
United Kingdom Investors:
Tiziana Life Sciences plcGabriele Cerrone,
Chairman and founder |
+44 (0)20 7495 2379 |
U.S. Investor Contact:
RedChip Companies, Inc.Dave
Gentry407-491-4498dave@redchip.com
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From Apr 2024 to May 2024
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From May 2023 to May 2024